News & Media

Read about our latest news and initiatives, and find more information about Acadia. 

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders.

Contacts

Media

Acadia Contact

Deb Kazenelson

Phone

(818) 395-3043

Investors

Acadia Contact

Mark Johnson, CFA

Phone

(858) 752-8346